GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sutro Biopharma Inc (NAS:STRO) » Definitions » EPS without NRI

Sutro Biopharma (Sutro Biopharma) EPS without NRI : $-1.92 (TTM As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Sutro Biopharma EPS without NRI?

Sutro Biopharma's earnings per share without non-recurring items for the three months ended in Dec. 2023 was $0.43. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.92.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 0.20% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 14.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Sutro Biopharma's EPS without NRI or its related term are showing as below:

STRO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -1.5   Med: 6.1   Max: 29
Current: 0.2

During the past 8 years, Sutro Biopharma's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 29.00% per year. The lowest was -1.50% per year. And the median was 6.10% per year.

STRO's 3-Year EPS without NRI Growth Rate is ranked worse than
56.34% of 1301 companies
in the Biotechnology industry
Industry Median: 5.1 vs STRO: 0.20

Sutro Biopharma's EPS (Diluted) for the three months ended in Dec. 2023 was $0.52. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.78.

Sutro Biopharma's EPS (Basic) for the three months ended in Dec. 2023 was $0.52. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.78.


Sutro Biopharma EPS without NRI Historical Data

The historical data trend for Sutro Biopharma's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sutro Biopharma EPS without NRI Chart

Sutro Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial -2.43 -1.92 -2.19 -2.54 -1.91

Sutro Biopharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.82 -0.76 -0.78 -0.82 0.43

Competitive Comparison of Sutro Biopharma's EPS without NRI

For the Biotechnology subindustry, Sutro Biopharma's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sutro Biopharma's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sutro Biopharma's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Sutro Biopharma's PE Ratio without NRI falls into.



Sutro Biopharma EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sutro Biopharma  (NAS:STRO) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Sutro Biopharma EPS without NRI Related Terms

Thank you for viewing the detailed overview of Sutro Biopharma's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Sutro Biopharma (Sutro Biopharma) Business Description

Traded in Other Exchanges
Address
111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Sutro Biopharma Inc is clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
Executives
Hans-peter Gerber officer: Chief Scientific Officer C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Brunilda Shtylla officer: Chief Business Officer C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080
Venkatesh Srinivasan officer: Chief Tech Op Officer C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080
Anne Elizabeth Borgman officer: Chief Medical Officer 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
William J Newell director, officer: CEO & President 887 GREAT NORTHERN WAY, VANCOUVER A1 V5T 4T5
Heidi Hunter director C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080
Nicki Vasquez officer: Chief Port. Strat & Alnce Ofcr C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080
Jane Chung officer: Chief Commercial Officer C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080
Trevor Hallam officer: Chief Science Officer PALATIN TECHNOLOGIES, INC., 4C CEDAR BROOK DRIVE, CRANBURY NJ 08512
Jon Marc Wigginton director 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
John Gordon Freund director, 10 percent owner 125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301
Arturo Md Molina officer: Chief Medical Officer 10990 WILSHIRE BLVD, SUITE 1200, LOS ANGELES CA 90024
Linda A Fitzpatrick officer: Chief People & Comm. Officer NUVELO, INC., 675 ALMANOR AVENUE, SUNNYVALE CA 94085
James P Panek director C/O VAXGEN INC, 1000 MARINA BLVD. #200, BRISBANE CA 94005
Matsui Connie director 3030 CALLAN RD, SAN DIEGO CA 92121

Sutro Biopharma (Sutro Biopharma) Headlines